Targeting of radio-isotopes for cancer therapy

Cancer Biology and Therapy

Volumn 3, Issue 4, 2004, Pages 361-370

  Milenic, Diane E ^a   Brechbiel, Martin W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bifunctional chelating agent; Monoclonal antibody; Radioimmunoconsurjgates; Radioimmunotherapy

Indexed keywords

ACTINIUM; ASTATINE 211; BISMUTH; BISMUTH 213; CETUXIMAB; COPPER 67; COTARA; DOXORUBICIN; EPRATUZUMAB; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INTERLEUKIN 2 RECEPTOR ANTIBODY; IODINE 125; IODINE 131; LABETUZUMAB; LEAD 212; LUTETIUM; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LYM 1; ONCOLYM; PACLITAXEL; PEMTUMOMAB; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; RHENIUM 188; RITUXIMAB; SAMARIUM 153; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90; ANTIBODY CONJUGATE; RADIOISOTOPE;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COMPLEX FORMATION; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HALF LIFE TIME; HUMAN; ISOTOPE LABELING; LUNG CANCER; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; RADIOIMMUNOTHERAPY; REVIEW; STOMACH CANCER; THROMBOCYTOPENIA; CHEMISTRY; IMMUNOLOGY; NEOPLASM;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; HUMANS; IMMUNOCONJUGATES; NEOPLASMS; RADIOISOTOPES;

EID: 2642529204     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.4.790     Document Type: Review

References (90)

1. Kohler G, Milstein C. Continous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7.
2. Ehrlich P, Herta CA, Shigas K. Ueber einige verwendungen der naphtochinosuflsaure. Ztschr f Physiol Chem 1904; 61:379-92.
3. Schlom J. Monoclonal antibodies: They're more and less than you think. In: Broder S, ed. Molecular Foundations of Oncology. Baltimore, MD: Williams and Wilkins, 1990:95-134.
4. Milenic DE. Radioimmunotherapy: Designer molecules to potentiate effective therapy. Semin Radiat Oncol 2000; 10:139-55.
5. Glennie MJ, van de Winkel JGJ. Renaissance of cancer therapeutic antibodies. DDT 2003; 8:503-10.
6. Herlyn D, Herlyn M, Steplewski Z, Koprowski H. Monoclonal anti-human tumor antibodies of six isotypes in cytotoxic reactions with human and murine effector cells. Cell Immunol 1985; 92:105-14.
7. Copper NR. The complement system. In: Stittes DP, Stobo JD, Wells JV eds. Norwalk, CT: Appleton & Lange, 1987:114-27.
8. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med 2000; 6:443-6.
9. Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003; 30:3-8.
10. Trauth B, Klas C, Peters AM, Matzku S, Moller P, Falk W, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245:301-5.
11. Baselga J, Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther 1994; 64:127-54.
12. Cragg MS, French RR, Glennie MJ. Signaling antibodies in cancer therapy. Cur Opin Immunol 1999; 11:541-7.
13. Deans JP, Schieven GL, Shu GL, Valentine MA, Gilliland LA, Aruffo A, et al. Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2. J Immunol 1993; 151:4494-504.
14. Maloney DG, Grillo-Lopez A J, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade nonHodgkin's lymphoma. Blood 1998; 90:2188-95.
15. Uchiyama T, Nelson DL, Fleisher TA, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. J Immunol 1981; 126:1398-403.
16. Junghans RP, Waldmann TA, Landolfi NF, et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 1990; 50:14951-502.
17. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21:309-18.
18. Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, et al. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regulat 1991; 1:72-82.
19. Pietras RJ, Poen JC, Gallardo D, et al. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999; 59:1347-55.
20. Hortobagyi GN, Perez EA. Integration of trastuzumab into adjuvant systemic therapy of breast cancer: Ongoing and planned clinical trials. Semin Oncol 2001; 28:41-6.
21. Srivastava S, Dadachova E. Recent advances in radionuclide therapy. Semin Nucl Med 2001; 31:330-41.
22. Geerlings MW. Radionuclides for radioimmunotherapy: Criteria for selection. Int J Biol Markers 1993; 8:180-6.
23. Kassis AI, Harapanhalli RS, Adelstein SJ. Comparison of strand breaks in plasmid DNA after positional changes of auger electron-emitting iodine-125. Radiation Res 1999; 151:167-76.
24. Makrigiorgos G, Adelstein SJ, Kassis AI. Auger electron emitters: Insights gained from in vitro experiments. Radiat Environ Biophys 1990; 29:75-91.
25. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 1986; 27:1490-7.
26. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995; 36:1902-9.
27. Knox SJ, Meredith RF. Clinical radioimmunotherapy. Semin Radiat Oncol 2000; 10:73-93.
28. Mulligan T, Carrasquillo JA, Chung Y, Milenic DE, Schlom J, Feuerstein I, et al. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res 1995; 1:1447-54.
29. 177Lu-CC49: A Phase I/II study. Gynecol Oncol 1997; 65:94-101.
30. 67Cu-2IT-BAT-Lym-1 for nonHodgkin's lymphoma. J Nucl Med 1999; 40:2014-20.
31. Kurtzman SH, Russo A, Mitchell JB, DeGraff W, Sindelar WF, Brechbiel MW, et al. 212Bismuth linked to an antipancreatic carcinoma antibody: Model for alpha-particle-emitter radioimmunotherapy. J Natl Cancer Inst 1988; 80:449-52.
32. Bethge WA, Wilbur DS, Storb R, Hamlin DK, Santos EB, Brechbiel MW, et al. Selective T-cell ablation with bismuth-213 labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood 2003; 101:5068-75.
33. Thorpe PE, Derbyshire EJ. Targeting of vasculature of solid tumors. J Controlled Release 1997; 48:277-88.
34. Packard AB, Kronauge JF, Brechbiel MW. Metalloradiopharmaceuticals. In: Clarke, M.J., Sadler, P.J., eds. A Metalloradiopharmaceuticals II, Diagnosis and Therapy Eds. NY: Spriner-Verlag, 1999:45-116.
35. Ruegg CL, Anderson-Berg WT, Brechbiel MW, et al. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res 1990; 50:4221-6.
36. Brechbiel MW, Gansow OA. Synthesis of C-functionalized trans-cyclohexyldiethylene-triamine-pentaacetic acids for labelling ofmonoclona antibodies with the bismuth-212 α-particle emitter. J Chem Soc Trans 1992; 1173-8.
37. Milenic DE, Roselli M, Mirzadeh S, Pippin CG, Gansow OA, Colcher D, et al. In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. Cancer Biotherap Radiopharm 2001; 16:133-46.
38. Schott ME, Schlom J, Siler K, Milenic DE, Eggensberger D, Colcher D, et al. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates. Cancer 1994; 73:993-8.
39. Roselli M, Milenic DE, Brechbiel MW, Mirzadeh S, Pippin CG, Gansow OA, et al. In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts. Cancer Biotherap Radiopharm 1999; 14:209-20.
40. 177Lu for radioimmunotherapeutic applications. Nuc Med Biol 2002; 29:431-42.
41. Novak-Hofer I, Schubiger PA. Copper-67 as a therapeutic nuclide for radioimmunotherapy. Eur J Nucl Med 2002; 29:821-30.
42. 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of nonHodgkin's lymphoma: A pilot study. Anticancer Res 1998; 18:2779-88.
43. Bass LA, Wang M, Welch MJ, Anderson CJ. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem 2000; 11:527-32.
44. Rogers BE, Anderson CJ, Connett JM, Guo LW, Edwards WB, Sherman EL, et al. Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: Biodistribution and metabolism. Bioconjug Chem 1996; 7:511-22.
45. Meredith RF, LoBuglio AF, Spencer EB. Recent progress in radioimmunotherapy for cancer. Oncology 1997; 11:979-84.
46. DeNardo GL, DeNardo SJ, O'Grady LF, Hu E, Systma VM, Mills SL, et al. Treatment of B-cell malignancies with I-131 Lym-1 monoclonal antibodies. Int J Cancer 1988; 3:96-101.
47. 131I-LYM-1 antibody for fractionated radioimmunotherapy of nonHodgkins lymphoma. J Clin Oncol 1998; 16:3246-3256.
48. Durbin PW. Metabolic characteristics within a chemical family. Health Phys 1960; 2:225-38.
49. 67Cu-versus 131I-labeled Lym-1 antibody: Comparative pharmacokinetics and dosimetry in patients with nonHodgkins lymphoma. Clin Cancer Res 1999; 5:533-41.
50. DeNardo SJ, Richman CM, Goldstein DS, Shen S, Salako Q, Kukis DL, et al. Ytrrium-90/Indium-111-DOTA-Peptide-Chimeric L6: Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res 1997; 17:1735-44.
51. Li M, Meares CF. Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. Bioconjug Chem 1993; 4:275-83.
52. DeNardo SJ, DeNardo GL, Yuan A, Richman CM, O'Donnell RT, Lara PN, et al. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: Comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane- N, N′,N″,N‴-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT Clin Cancer Res 2003; 9:3938s-44s.
53. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996; 2:457-70.
54. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell nonHodgkin's lymphoma. J Clin Oncol 2002; 20:2453-63.
55. Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/ refractory low-grade and transformed low-grade B-cell nonHodgkin's lymphoma. J Clin Oncol 2000; 18:1316-23.
56. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell nonHodgkin's lymphomas. J Clin Oncol 2001; 19:3918-28.
57. Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 1995; 86:4063-75.
58. Jurcic JG, Caron PC, Nikula TK, Papdopoulos EB, Finn RD, Gansow OA, et al. Radiolabeled anti-CD33 monoclonal antibody for myeloid leukemias. Clin Canc Res 1995; 55:5908s-10s.
59. Jurcic JG, Divgi CR, McDevitt MR, et al. Potential for myeloablation with yttrium-90-HuM195 (anti-CD33) in myeloid leukemia. Proc Am Soc Clin Oncol 2000; 19:7a.
60. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002; 100:1233-9.
61. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. New Eng J Med 1993; 329:1219-24.
62. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346:336-40.
63. Gopal AK, Gooley TA, Maloney DG, Petersdorf SH, Eary JF, Rajendran JG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular nonHodgkin lymphoma: a multivariable cohort analysis. Blood 2003; 102:2351-7.
64. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, nd autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96:2934-42.
65. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular nonHodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003; 102:1606-12.
66. 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemiaand myelodysplastic syndrome. Blood 1999; 94:1237-47.
67. Meredith RF, Khazaeli MB, Plott WE, Saleh MN, Liu T, Allen LF, et al. Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med 1992; 33:23-9.
68. Meredith RF, Khazaeli MB, Liu T, Plott G, Wheeler RH, Russell C, et al. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med 1992; 33:1648-53.
69. Scott AM, Divig CR, Kemeny N, et al. Radioimmunotherapy with I-131 labeled monoclonal antibody CC49 in colorectal cancer. Eur J Nucl Med 1992; 19:709.
70. Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH, et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody. J Nucl Med 1994; 35:1017-22.
71. Tempero M, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlom J, et al. High-dose therapy with iodine-131-labeled monoclonal CC49 in patients with gastroinstestinal cancers: A Phase I trial. J Clin Oncol 1997; 15:1518-28.
72. Meredith RF, Alvarez RD, Partridge EE, Khazaeli MB, Lin CY, Macey DJ. Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study. Cancer Biother Radiopharm 2001; 16:305-15.
73. Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, et al. A Phase I study of combined modality 90ytttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer Clin Cancer Res 2002; 8:2806-11.
74. 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I. Clin Cancer Res 1996; 2:963-72.
75. Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. J Clin Oncol 1998; 16:2202-12.
76. Cokgar I, Akabani G, Kuan C-T, Friedman HS, Friedman AH, Coleman RE, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 2000; 18:3862-72.
77. 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002; 20:1389-97.
78. Zalutsky M, Reardon D, Akabani G, Friedman A, Friedman H, Herndon J, et al. Astatine-211 labeled human/mouse chimeric anti-tenascin monoclonal antibody via surgically created resection cavities for patients with recurrent glioma: Phase I study. Neuro-Oncol 2002; 4:S103.
79. Bardies M, Bardet S, FaivreChauvet A, Peltier P, Douillard J-Y, Mahe M, et al. Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer J Nucl Med 1996; 37:1853-9.
80. Kalofonos HP, Rusckowski M, Siebecker DA Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: Preliminary communication. J Nucl Med 1990; 31:1791-6.
81. Paganelli G, Belloni C, Magnani P, Zito F, Pasini A, Sassi I, et al. Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. Eur J Nucl Med 1992; 19:322-9.
82. Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De Braud F, et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 1999; 26:348-57.
83. Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: A pilot study. Br J Cancer 2002; 86:207-12.
84. Paganelli G, Bartolomei M, Ferrari M, Broggi G, Sturiale C, Grana C, et al. Pretargeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: Phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 2001; 16:227-35.
85. Breitz HB, Weiden PL, Beaumier PL, Axworthy DB, Seiler C, Su FM, et al. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. J Nucl Med 2000; 41:131-40.
86. Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/strepavidin in patients with metastatic colon cancer. Clin Cancer Res 2000; 6:406-14.
87. Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of nonHodgkin's lymphoma (NHL): Initial Phase I/II study results. Cancer Biother Radiopharm 2000; 15:15-29.
88. Zelentz AD. A clinical and scientific overview of tositumomab and iodine I131 tositumomab. Sem Oncol 2003; 30:22-30.
89. Cardillo TM, Blumenthal R, Ying Z, Gold DV. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer, Int J Cancer 2002; 97:386-92.
90. Harari PM, Huang S-H. Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001; 49:427-433.